INT49258

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1995
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 7.24
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (EDN1) extracellular region (EDN1) cell-cell signaling (EDN1)
cytoplasm (EDN1)
Anatomy Link Frequency
proximal 2
smooth muscle cells 2
pulmonary artery 2
optic nerve 2
EDN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 60 99.98 Very High Very High Very High
Calcium channel 15 99.74 Very High Very High Very High
metalloproteinase 10 94.84 High High
ischemia 20 89.12 High High
Inflammatory response 4 89.00 High High
cva 30 81.84 Quite High
Osteoarthritis 70 79.12 Quite High
Migraine 5 72.88 Quite High
cytokine 8 57.36 Quite High
Inflammation 19 56.00 Quite High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 486 99.92 Very High Very High Very High
Hypertension 3 99.88 Very High Very High Very High
Cancer 101 99.80 Very High Very High Very High
Scotoma 2 98.68 Very High Very High Very High
Stress 11 97.56 Very High Very High Very High
Increased Venous Pressure Under Development 125 97.20 Very High Very High Very High
Glaucoma 101 95.80 Very High Very High Very High
Congenital Anomalies 18 94.12 High High
Injury 13 91.44 High High
Amaurosis Fugax 1 90.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The amount of ET-1 generated from exogenously applied big ET-1 was markedly decreased by phosphoramidon in a concentration-dependent manner.
Negative_regulation (decreased) of Positive_regulation (generated) of ET-1
1) Confidence 0.43 Published 1995 Journal Biol. Pharm. Bull. Section Abstract Doc Link 7550091 Disease Relevance 0 Pain Relevance 0
Immediately after the initial release of the proximal and distal clamps, venous oxygen content dramatically decreased from 11.3 to 3.6 mL/dL (vol%) with significant increases in venous ET-1 concentration from 2.3 to 4.9 pg/mL.
Negative_regulation (decreased) of Positive_regulation (increases) of ET-1 in proximal
2) Confidence 0.43 Published 1995 Journal J. Cardiothorac. Vasc. Anesth. Section Body Doc Link 8547550 Disease Relevance 0 Pain Relevance 0
Several studies show that calcium channel antagonists reduce the effect of increased levels of ET-1 on ocular perfusion and improve visual field defects through induced vasodilation (Flammer et al 2001).
Negative_regulation (reduce) of Positive_regulation (increased) of ET-1 associated with scotoma, antagonist, calcium channel and increased venous pressure under development
3) Confidence 0.41 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699797 Disease Relevance 1.58 Pain Relevance 0.61
This agent not only suppressed the ET-1-induced stimulation, but also decreased the level of both enzymes below the basal level: a significant difference was found for both MMP-13 and MMP-1 when compared with the ET-1 stimulation (P < 0.005) and for MMP-13 when compared with the control (P < 0.05).
Negative_regulation (suppressed) of Positive_regulation (stimulation) of ET-1-induced
4) Confidence 0.38 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.10 Pain Relevance 0
The inhibition of p38 kinase is associated with a suppression of the ET-1-induced stimulation of both enzymes, whereas the inhibitions of adenyl cyclase-dependent PKA kinase is associated with a partial suppression of the ET-1-induced stimulation of MMP-13 production only.
Spec (partial) Negative_regulation (suppression) of Positive_regulation (stimulation) of ET-1-induced
5) Confidence 0.38 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.20 Pain Relevance 0.13
RESULTS: The patient was found to have a temporary ocular blood flow dysregulation and increased plasma endothelin-1 levels which decreased after the acute phase of the optic nerve.
Negative_regulation (decreased) of Positive_regulation (increased) of endothelin-1 in optic nerve
6) Confidence 0.37 Published 2003 Journal Ophthalmologica Section Body Doc Link 14573982 Disease Relevance 0.09 Pain Relevance 0
Most patients with pulmonary artery hypertension have elevated EDN1 levels, and pharmacological blockage of EDN1 activity leads to clinical improvement and better prognosis [81].
Negative_regulation (blockage) of Positive_regulation (elevated) of EDN1 in pulmonary artery associated with hypertension
7) Confidence 0.36 Published 2007 Journal PLoS Genetics Section Body Doc Link PMC1994710 Disease Relevance 0.91 Pain Relevance 0.08
Interestingly, the addition of BQ 123 blocked the ET-1-induced proteinase activation and tumor cell migration and invasion.
Negative_regulation (blocked) of Positive_regulation (activation) of ET-1-induced associated with cancer
8) Confidence 0.23 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.82 Pain Relevance 0.20
This imbalance consisting of reduced production of prostacyclin and nitric oxide and upregulation of ET-1 resulting in the abnormal proliferation and contraction of pulmonary smooth muscle cells via three pathways, all of which are potential targets for therapy (Figure 1 and Table 2) (Humbert, Sitbon et al 2004).
Negative_regulation (reduced) of Positive_regulation (upregulation) of ET-1 in smooth muscle cells
9) Confidence 0.04 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 0.77 Pain Relevance 0.10
Central to the development of PAH is reduced production of prostacyclin (PGI2), nitric oxide (NO) and vasoactive intestinal peptide (VIP), with upregulation of endothelin 1 (ET-1) (Humbert, Sitbon et al 2004).
Negative_regulation (reduced) of Positive_regulation (upregulation) of endothelin associated with pulmonary hypertension
10) Confidence 0.04 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 1.38 Pain Relevance 0
Central to the development of PAH is reduced production of prostacyclin (PGI2), nitric oxide (NO) and vasoactive intestinal peptide (VIP), with upregulation of endothelin 1 (ET-1) (Humbert, Sitbon et al 2004).
Negative_regulation (reduced) of Positive_regulation (upregulation) of ET-1 associated with pulmonary hypertension
11) Confidence 0.04 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 1.38 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox